Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s diseaseSimon Dujardin, Bradley T. Hyman, Caitlin Commins et al.|Nature Medicine|2020Cited by 445
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patientsMatthew Kennedy, Mark S. Forman, Jack D. Scott et al.|Science Translational Medicine|2016Cited by 416
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase InhibitionMatthew Fell, John A. Morrow, Christian Mirescu et al.|Journal of Pharmacology and Experimental Therapeutics|2015Cited by 336
Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s DiseaseJack D. Scott, Andrew W. Stamford, Sarah W. Li et al.|Journal of Medicinal Chemistry|2016Cited by 165
Structure based design of iminohydantoin BACE1 inhibitors: Identification of an orally available, centrally active BACE1 inhibitorJared N. Cumming, Andrew W. Stamford, Elizabeth M. Smith et al.|Bioorganic & Medicinal Chemistry Letters|2012Cited by 153